Antimalarial activity of the myxobacterial macrolide chlorotonil A

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 11, 2014, Pages 6378-6384

  Held, Jana ^a,b,c   Gebru, Tamirat ^a,c   Kalesse, Markus ^d,e   Jansen, Rolf ^c,e   Gerth, Klaus ^e   Müller, Rolf ^c,e,f   Mordmüller, Benjamin ^a,b,c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b German Center for Infection Research CERMEL   (Gabon)

^c Center for Structural Systems Biology Helmholtz   (Germany)

^d LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^e HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^f SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTESUNATE; CHLOROQUINE; CHLOROTONIL A; DIHYDROARTEMISININ; EPOXOMICIN; MACROLIDE; PLACEBO; UNCLASSIFIED DRUG; ARTEMISININ DERIVATIVE; CHLORINATED HYDROCARBON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE TRANSMISSION; ERYTHROCYTE; GABON; GAMETOCYTE; IC50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MYXOCOCCALES; NONHUMAN; PARASITE DEVELOPMENT; PLASMODIUM BERGHEI; PLASMODIUM BERGHEI INFECTION; PLASMODIUM FALCIPARUM; RODENT MALARIA; SORANGIUM CELLULOSUM; ANIMAL; BAGG ALBINO MOUSE; DRUG EFFECTS; DRUG SENSITIVITY; ISOLATION AND PURIFICATION; MALARIA, FALCIPARUM; METABOLISM; PARASITEMIA; PARASITOLOGY;

ANIMALS; ANTIMALARIALS; ARTEMISININS; CHLOROQUINE; HYDROCARBONS, CHLORINATED; MACROLIDES; MALARIA, FALCIPARUM; MICE; MICE, INBRED BALB C; MYXOCOCCALES; PARASITEMIA; PARASITIC SENSITIVITY TESTS; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM;

EID: 84908568530     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03326-14     Document Type: Article

References (53)

1. WHO. 2013. World malaria report, 2013. WHO, Geneva, Switzerland.
2. Greenwood BM, Targett GA. 2011. Malaria vaccines and the new malaria agenda. Clin. Microbiol. Infect. 17:1600-1607. http://dx.doi.org/10.1111/j.1469-0691.2011.03612.x.
3. The RTS,S Clinical Trials Partnership. 2012. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N. Engl. J. Med. 367:2284-2295. http://dx.doi.org/10.1056/NEJMoa1208394.
4. Petersen I, Eastman R, Lanzer M. 2011. Drug-resistant malaria: molecular mechanisms and implications for public health. FEBS Lett. 585:1551-1562. http://dx.doi.org/10.1016/j.febslet.2011.04.042.
5. D'Alessandro U, Buttiens H. 2001. History and importance of antimalarial drug resistance. Trop. Med. Int. Health 6:845-848. http://dx.doi.org/10.1046/j.1365-3156.2001.00819.x.
6. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. 2008. Evidence of artemisinin-resistant malaria in western Cambodia. N. Engl. J. Med. 359:2619-2620. http://dx.doi.org/10.1056/NEJMc0805011.
7. WHO. 2011. Guidelines for the treatment of malaria, 2nd ed. WHO, Geneva, Switzerland.
8. Tschan S, Kremsner PG, Mordmuller B. 2012. Emerging drugs for malaria. Expert Opin. Emerg. Drugs 17:319-333. http://dx.doi.org/10.1517/14728214.2012.702754.
9. Kremsner PG, Krishna S. 2004. Antimalarial combinations. Lancet 364: 285-294. http://dx.doi.org/10.1016/S0140-6736(04)16680-4.
10. Dechy-Cabaret O, Benoit-Vical F. 2012. Effects of antimalarial molecules on the gametocyte stage of Plasmodium falciparum: the debate. J. Med. Chem. 55:10328-10344. http://dx.doi.org/10.1021/jm3005898.
11. Alonso PL, Brown G, Arevalo-Herrera M, Binka F, Chitnis C, Collins F, Doumbo OK, Greenwood B, Hall BF, Levine MM, Mendis K, Newman RD, Plowe CV, Rodriguez MH, Sinden R, Slutsker L, Tanner M. 2011. A research agenda to underpin malaria eradication. PLoS Med. 8:e1000406. http://dx.doi.org/10.1371/journal.pmed.1000406.
12. Newman DJ, Cragg GM. 2012. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod. 75:311-335. http://dx.doi.org/10.1021/np200906s.
13. Bagchi GD, Jain DC, Kumar S. 1997. Arteether: a potent plant growth inhibitor from Artemisia annua. Phytochemistry 45:1131-1133. http://dx.doi.org/10.1016/S0031-9422(97)00126-X.
14. Frey M, Chomet P, Glawischnig E, Stettner C, Grun S, Winklmair A, Eisenreich W, Bacher A, Meeley RB, Briggs SP, Simcox K, Gierl A. 1997. Analysis of a chemical plant defense mechanism in grasses. Science 277: 696-699. http://dx.doi.org/10.1126/science.277.5326.696.
15. Rosenthal GA, Berenbaum MR. 1981. Herbivores: their interactions with secondary plant metabolites, volume 1: the chemical participants, 2nd ed. Academic Press, New York, NY.
16. Laska M, Rivas Bautista RM, Hernandez Salazar LT. 2009. Gustatory responsiveness to six bitter tastants in three species of nonhuman primates. J. Chem. Ecol. 35:560-571. http://dx.doi.org/10.1007/s10886-009-9630-8.
17. Sayers EW, Barrett T, Benson DA, Bryant SH, Canese K, Chetvernin V, Church DM, DiCuccio M, Edgar R, Federhen S, Feolo M, Geer LY, Helmberg W, Kapustin Y, Landsman D, Lipman DJ, Madden TL, Maglott DR, Miller V, Mizrachi I, Ostell J, Pruitt KD, Schuler GD, Sequeira E, Sherry ST, Shumway M, Sirotkin K, Souvorov A, Starchenko G, Tatusova TA, Wagner L, Yaschenko E, Ye J. 2009. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res. 37:D5-D15. http://dx.doi.org/10.1093/nar/gkn741.
18. Benson DA, Karsch-Mizrachi I, Lipman DJ, Ostell J, Sayers EW. 2009. GenBank. Nucleic Acids Res. 37:D26-D31.
19. Gerth K, Pradella S, Perlova O, Beyer S, Muller R. 2003. Myxobacteria: proficient producers of novel natural products with various biological activities-past and future biotechnological aspects with the focus on the genus Sorangium. J. Biotechnol. 106:233-253. http://dx.doi.org/10.1016/j .jbiotec.2003.07.015.
20. Schneiker S, Perlova O, Kaiser O, Gerth K, Alici A, Altmeyer MO, Bartels D, Bekel T, Beyer S, Bode E, Bode HB, Bolten CJ, Choudhuri JV, Doss S, Elnakady YA, Frank B, Gaigalat L, Goesmann A, Groeger C, Gross F, Jelsbak L, Jelsbak L, Kalinowski J, Kegler C, Knauber T, Konietzny S, Kopp M, Krause L, Krug D, Linke B, Mahmud T, Martinez-Arias R, McHardy AC, Merai M, Meyer F, Mormann S, Munoz-Dorado J, Perez J, Pradella S, Rachid S, Raddatz G, Rosenau F, Ruckert C, Sasse F, Scharfe M, Schuster SC, Suen G, Treuner-Lange A, Velicer GJ, Vorholter FJ, Weissman KJ, Welch RD, Wenzel SC, Whitworth DE, Wilhelm S, Wittmann C, Blocker H, Puhler A, Muller R. 2007. Complete genome sequence of the myxobacterium Sorangium cellulosum. Nat. Biotechnol. 25:1281-1289. http://dx.doi.org/10.1038/nbt1354.
21. Diez J, Martinez JP, Mestres J, Sasse F, Frank R, Meyerhans A. 2012. Myxobacteria: natural pharmaceutical factories. Microb. Cell Fact. 11:52. http://dx.doi.org/10.1186/1475-2859-11-52.
22. Weissman KJ, Muller R. 2010. Myxobacterial secondary metabolites: bioactivities and modes-of-action. Nat. Prod. Rep. 27:1276-1295. http://dx.doi.org/10.1039/c001260m.
23. Wenzel SC, Müller R. 2009. The biosynthetic potential of myxobacteria and their impact in drug discovery. Curr. Opin. Drug Discov. Dev. 12: 220-230.
24. Gerth K, Steinmetz H, Hofle G, Jansen R. 2008. Chlorotonil A, a macrolide with a unique gem-dichloro-1,3-dione functionality from Sorangium cellulosum, So ce1525. Angew. Chem. Int. Ed. Engl. 47:600-602. http://dx.doi.org/10.1002/anie.200703993.
25. Rahn N, Kalesse M. 2008. The total synthesis of chlorotonil A. Angew. Chem. Int. Ed. Engl. 47:597-599. http://dx.doi.org/10.1002/anie.20070 3930.
26. Trager W, Jensen JB. 1976. Human malaria parasites in continuous culture. Science 193:673-675. http://dx.doi.org/10.1126/science.781840.
27. Lambros C, Vanderberg JP. 1979. Synchronization of Plasmodium falciparum erythrocytic stages in culture. J. Parasitol. 65:418-420. http://dx.doi.org/10.2307/3280287.
28. Noedl H, Bronnert J, Yingyuen K, Attlmayr B, Kollaritsch H, Fukuda M. 2005. Simple histidine-rich protein 2 double-site sandwich enzymelinked immunosorbent assay for use in malaria drug sensitivity testing. Antimicrob. Agents Chemother. 49:3575-3577. http://dx.doi.org/10.1128/AAC.49.8.3575-3577.2005.
29. Held J, Westerman R, Kremsner PG, Mordmuller B. 2010. In vitro activity of mirincamycin (U24729A) against Plasmodium falciparum isolates from Gabon. Antimicrob. Agents Chemother. 54:540-542. http://dx.doi.org/10.1128/AAC.01090-09.
30. Peters W. 1970. The chemotherapy of rodent malaria. X. Dynamics of drug resistance. II. Acquisition and loss of chloroquine resistance in Plasmodium berghei observed by continuous bioassay. Ann. Trop. Med. Parasitol. 64:25-40.
31. Fidock DA, Rosenthal PJ, Croft SL, Brun R, Nwaka S. 2004. Antimalarial drug discovery: efficacy models for compound screening. Nat. Rev. Drug Discov. 3:509-520. http://dx.doi.org/10.1038/nrd1416.
32. Lelièvre J, Almela MJ, Lozano S, Miguel C, Franco V, Leroy D, Herreros E. 2012. Activity of clinically relevant antimalarial drugs on Plasmodium falciparum mature gametocytes in an ATP bioluminescence "transmission blocking" assay. PLoS One 7:e35019. http://dx.doi.org/10.1371/journal .pone.0035019.
33. Ritz C, Streibig JC. 2005. Bioassay analysis using R. J. Stat. Software 12:1-22.
34. R Development Core Team. 2009. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
35. Nicolaou KC, Winssinger N, Pastor J, Ninkovic S, Sarabia F, He Y, Vourloumis D, Yang Z, Li T, Giannakakou P, Hamel E. 1997. Synthesis of epothilones A and B in solid and solution phase. Nature 387:268-272. http://dx.doi.org/10.1038/387268a0.
36. Irschik H, Reichenbach H, Hofle G, Jansen R. 2007. The thuggacins, novel antibacterial macrolides from Sorangium cellulosum acting against selected Gram-positive bacteria. J. Antibiot. (Tokyo) 60:733-738. http://dx.doi.org/10.1038/ja.2007.95.
37. Reichenbach H, Höfle G. 2008. Discovery and development of the epothilones: a novel class of antineoplastic drugs. Drugs R. D. 9:1-10.
38. Cristofanilli M. 2012. Advancements in the treatment of metastatic breast cancer (MBC): the role of ixabepilone. J. Oncol. 2012:703858. http://dx.doi.org/10.1155/2012/703858.
39. Goodman CD, Su V, McFadden GI. 2007. The effects of anti-bacterials on the malaria parasite Plasmodium falciparum. Mol. Biochem. Parasitol. 152:181-191. http://dx.doi.org/10.1016/j.molbiopara.2007.01.005.
40. Dahl EL, Rosenthal PJ. 2007. Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. Antimicrob. Agents Chemother. 51:3485-3490. http://dx.doi.org/10.1128/AAC.00527-07.
41. Skinner TS, Manning LS, Johnston WA, Davis TM. 1996. In vitro stage-specific sensitivity of Plasmodium falciparum to quinine and artemisinin drugs. Int. J. Parasitol. 26:519-525.
42. Mombo-Ngoma G, Oyakhirome S, Ord R, Gabor JJ, Greutelaers KC, Profanter K, Greutelaers B, Kurth F, Lell B, Kun JF, Issifou S, Roper C, Kremsner PG, Grobusch MP. 2011. High prevalence of dhfr triple mutant and correlation with high rates of sulphadoxine-pyrimethamine treatment failures in vivo in Gabonese children. Malar. J. 10:123. http://dx.doi.org/10.1186/1475-2875-10-123.
43. Borrmann S, Binder RK, Adegnika AA, Missinou MA, Issifou S, Ramharter M, Wernsdorfer WH, Kremsner PG. 2002. Reassessment of the resistance of Plasmodium falciparum to chloroquine in Gabon: implications for the validity of tests in vitro vs. in vivo. Trans. R. Soc. Trop. Med. Hyg. 96:660-663. http://dx.doi.org/10.1016/S0035-9203(02)90345-7.
44. Werawattanachai N, Towiwat P, Unchern S, Maher TJ. 2007. Neuropharmacological profile of tetrahydrofuran in mice. Life Sci. 80:1656-1663. http://dx.doi.org/10.1016/j.lfs.2007.01.050.
45. Jang KH, Nam SJ, Locke JB, Kauffman CA, Beatty DS, Paul LA, Fenical W. 2013. Anthracimycin, a potent anthrax antibiotic from a marinederived actinomycete. Angew. Chem. Int. Ed. Engl. 52:7822-7824. http://dx.doi.org/10.1002/anie.201302749.
46. Diem Thuy LT, Ngoc Hung L, Danh PT, Na-Bangchang K. 2008. Absence of time-dependent artesunate pharmacokinetics in healthy subjects during 5-day oral administration. Eur. J. Clin. Pharmacol. 64:993-998. http://dx.doi.org/10.1007/s00228-008-0506-6.
47. Borrmann S, Adegnika AA, Missinou MA, Binder RK, Issifou S, Schindler A, Matsiegui PB, Kun JF, Krishna S, Lell B, Kremsner PG. 2003. Short-course artesunate treatment of uncomplicated Plasmodium falciparum malaria in Gabon. Antimicrob. Agents Chemother. 47:901-904. http://dx.doi.org/10.1128/AAC.47.3.901-904.2003.
48. White NJ. 2013. Primaquine to prevent transmission of falciparum malaria. Lancet Infect. Dis. 13:175-181. http://dx.doi.org/10.1016/S1473-3099(12)70198-6.
49. Beshir KB, Sutherland CJ, Sawa P, Drakeley CJ, Okell L, Mweresa CK, Omar SA, Shekalaghe SA, Kaur H, Ndaro A, Chilongola J, Schallig HD, Sauerwein RW, Hallett RL, Bousema T. 2013. Residual Plasmodium falciparum parasitemia in Kenyan children after artemisinin-combination therapy is associated with increased transmission to mosquitoes and parasite recurrence. J. Infect. Dis. 208:2017-2024. http://dx.doi.org/10.1093/infdis/jit431.
50. Targett G, Drakeley C, Jawara M, von Seidlein L, Coleman R, Deen J, Pinder M, Doherty T, Sutherland C, Walraven G, Milligan P. 2001. Artesunate reduces but does not prevent posttreatment transmission of Plasmodium falciparum to Anopheles gambiae. J. Infect. Dis. 183:1254-1259. http://dx.doi.org/10.1086/319689.
51. D'Alessandro S, Silvestrini F, Dechering K, Corbett Y, Parapini S, Timmerman M, Galastri L, Basilico N, Sauerwein R, Alano P, Taramelli D. 2013. A Plasmodium falciparum screening assay for anti-gametocyte drugs based on parasite lactate dehydrogenase detection. J. Antimicrob. Chemother. 68:2048-2058. http://dx.doi.org/10.1093/jac/dkt165.
52. Dechy-Cabaret O, Benoit-Vical F. 2012. Effects of antimalarial molecules on the gametocyte stage of Plasmodium falciparum: the debate. J. Med. Chem. 55:10328-10344. http://dx.doi.org/10.1021/jm3005898.
53. Delves M, Plouffe D, Scheurer C, Meister S, Wittlin S, Winzeler EA, Sinden RE, Leroy D. 2012. The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites. PLoS Med. 9:e1001169. http://dx.doi.org/10.1371/journal.pmed.1001169.